





### 12th Annual

# Juravinski Cancer Centre (JCC) and Walker Cancer Centre Uro-Oncology Forum 2023

- Friday, April 14 Saturday, April 15, 2023
- Inn on the Twenty, Jordan, ON



# FINAL PROGRAM



#### **MEETING CHAIR**



## Aly-Khan Lalani

GU Disease Site Team Chair, Juravinski Cancer Centre Assistant Professor, McMaster University

#### SCIENTIFIC PROGRAM COMMITTEE

- Rahul Bansal
- Mira Goldberg
- Kimmen Quan
- Stephanie Tatzel

#### By the end of this meeting, participants will:

- Review the recent data updates for the treatment of genitourinary (GU) cancers
- Discuss regional opportunities to optimize the multidisciplinary care for patients with GU cancers
- Highlight studies that will help address ongoing questions for GU cancers



This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Urological Association.

You may claim a maximum of 7 hours of credit.

APRIL 2023 AGENDA

14	18:30	REGISTRATION OPENS Room: Valley (1st floor)
FRI	18:30 - 19:00	WELCOME RECEPTION
	19:00 - 20:00	DINNER
	20:00 - 20:30	KEYNOTE LECTURE
	20.00 20.00	The landscape (and opportunities) of GU clinical trials in Canada: Focus on activities of the Canadian Cancer Trials Group (CCTG)
		Sebastien Hotte Associate Professor, Department of Oncology, McMaster University
		Staff Oncologist, Juravinski Cancer Centre
	20:30	NETWORKING EVENING
	20.30	Vintner's Cellar (Lower ground floor)  Open to all attendees and industry representatives
15 SAT	07:00 - 08:00	BREAKFAST Room: Windows on the Twenty (2nd floor)
	Meeting room: Va	lley Room (1st floor)
	08:00 - 09:45	BLADDER CANCER SESSION MODERATORS: STEPHANIE TATZEL & HIMU LUKKA
	08:00 - 08:20	Superficial bladder cancer: State of the union Bobby Shayegan
	08:20 - 08:45	PET-MUSE study and bladder cancer trials: An update Som Mukherjee
	08:45 - 09:05	Advances in systemic treatment for urothelial carcinoma
	00.10 07.00	Scott North
		Professor, Division of Medical Oncology, University of Alberta Director of Medical Oncology, Cross Cancer Institute
	09:05 - 09:20	Challenging urothelial cases Stephanie Tatzel (lead), Eric Nguyen, Som Mukherjee, Bobby Shayegan
	09:20 - 09:45	Discussion and open floor
	09:45 - 10:15	BREAK Room: Windows on the Twenty (2nd floor)
	10:15 - 12:10	KIDNEY CANCER SESSION MODERATORS: RAHUL BANSAL & PIOTR ZAREBA
	10:15 - 10:40	Small renal masses and localized RCC - Surgical considerations  Tony Finelli Chief of Urology, UHN GU Site Lead, Princess Margaret Cancer Centre Professor, University of Toronto
	10:40 - 11:00	Localized RCC - Non-surgical approaches Samantha Sigurdson
	11:00 - 11:20	Update on kidney cancer pathology with insights from CKCis Michael Bonert
	11:20 - 11:40	Adjuvant therapy and RCC cancer trials: An update Aly-Khan Lalani
	11:40 - 11:55	Challenging renal cases Rahul Bansal (lead), Luisa Cardenas, Samantha Sigurdson,
	11:55 - 12:10	Piotr Zareba  Discussion and open floor
	12:10 - 13:00	TEAM PHOTO & LUNCH
		Room: Windows on the Twenty (2nd floor)
	13:00 - 16:00	PROSTATE CANCER SESSION MODERATORS: KIMMEN QUAN & MICHAEL LEVESQUE
	13:00 - 13:20	Prostate cancer surviorship RADICAL PC upate Jehonathan Pinthus
	13:20 - 13:45	PSMA PET and lutetium in 2023 Sebastien Hotte, Katherine Zukotynski
	13:45 - 14:00	Challenging prostate cases Kimmen Quan (lead), CB Allard, Abhirami Hallock, Sebastien Hotte
	14:00 - 14:10	Discussion and open floor
	14:10 - 14:20	BREAK Meeting room: Valley Room (1st floor)
	14:20 - 15:00	Prostate trial updates Daniel Schep
	15:00 - 15:25	Metastatic CSPC - Which drugs to which patients?  Michael Ong
		Assistant Professor of Medicine, University of Ottawa Division of Medical Oncology
	15.05	Medical Oncologist, The Ottawa Hospital
	15:25 - 15:50	The great debate: Are combinations with PARP inhibitors ready for first-line mCRPC? YAY - Lorin Dodbiba, NAY - Luisa Cardenas  Discussion and open floor

Discussion and open floor

16:00

CLOSING REMARKS & ADJOURNMENT ALY-KHAN LALANI

### THANK YOU TO OUR SPONSORS

**GOLD SPONSORS** 





A Novartis Company





SILVER SPONSORS



























